{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:20:49Z","timestamp":1790270449858,"version":"4.1.0"},"reference-count":77,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":323,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,31]]},"abstract":"<jats:p>Cystamine is commonly used as a transglutaminase inhibitor. This disulphide undergoes reduction in vivo to the aminothiol compound, cysteamine. Thus, the mechanism by which cystamine inhibits transglutaminase activity in vivo could be due to either cystamine or cysteamine, which depends on the local redox environment. Cystamine inactivates transglutaminases by promoting the oxidation of two vicinal cysteine residues on the enzyme to an allosteric disulphide, whereas cysteamine acts as a competitive inhibitor for transamidation reactions catalyzed by this enzyme. The latter mechanism is likely to result in the formation of a unique biomarker, N-(\u03b3-glutamyl)cysteamine that could serve to indicate how cyst(e)amine acts to inhibit transglutaminases inside cells and the body.<\/jats:p>","DOI":"10.1042\/bsr20180691","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T12:21:10Z","timestamp":1532694070000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Cystamine and cysteamine as inhibitors of transglutaminase activity\n                    <i>in vivo<\/i>"],"prefix":"10.1042","volume":"38","author":[{"given":"Thomas M.","family":"Jeitner","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.L.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"2021111619125995800_B1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2217\/fnl.09.17","article-title":"Transglutaminase activation in neurodegenerative diseases","volume":"4","author":"Jeitner","year":"2009","journal-title":"Future Neurol."},{"key":"2021111619125995800_B2","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/pro.2162","article-title":"Regulation of the activities of the mammalian transglutaminase family of enzymes","volume":"21","author":"Kl\u00f6ck","year":"2012","journal-title":"Protein Sci."},{"key":"2021111619125995800_B3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0197-4580(01)00224-X","article-title":"N(epsilon)(gamma-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia","volume":"22","author":"Nemes","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"2021111619125995800_B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnen\/62.1.14","article-title":"Transglutaminase cross-links in intranuclear inclusions in Huntington disease","volume":"62","author":"Zainelli","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2021111619125995800_B5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1096\/fj.03-0829fje","article-title":"Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson\u2019s disease","volume":"18","author":"Andringa","year":"2004","journal-title":"FASEB J."},{"key":"2021111619125995800_B6","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1007\/s12035-015-9413-x","article-title":"Tissue transglutaminase and its product isopeptide are increased in Alzheimer\u2019s disease and appswe\/ps1de9 double transgenic mice brains","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"2021111619125995800_B7","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1523\/JNEUROSCI.3263-04.2005","article-title":"Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice","volume":"25","author":"Halverson","year":"2005","journal-title":"J. Neurosci."},{"key":"2021111619125995800_B8","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1073\/pnas.0438021100","article-title":"Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"100","author":"Junn","year":"2003","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111619125995800_B9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1046\/j.1471-4159.1999.02018.x","article-title":"Tissue transglutaminase is increased in Huntington\u2019s disease brain","volume":"73","author":"Lesort","year":"1999","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B10","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1073\/pnas.96.13.7388","article-title":"Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington\u2019s disease brain nuclei","volume":"96","author":"Karpuj","year":"1999","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111619125995800_B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0197-0186(01)00060-2","article-title":"Evidence for a role for transglutaminase in Huntington\u2019s disease and the potential therapeutic implications","volume":"40","author":"Karpuj","year":"2002","journal-title":"Neurochem. Int."},{"key":"2021111619125995800_B12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1750-3639.2008.00197.x","article-title":"Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer\u2019s disease brain","volume":"19","author":"Wilhelmus","year":"2009","journal-title":"Brain Pathol."},{"key":"2021111619125995800_B13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003730","article-title":"Transglutaminase is a critical link between inflammation and hypertension","volume":"5","author":"Luo","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"2021111619125995800_B14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1055\/s-0036-1571343","article-title":"Newly-recognized roles of factor XIII in thrombosis","volume":"42","author":"Byrnes","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"2021111619125995800_B15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/jnc.13203","article-title":"Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E\u2019s protective effects towards amyloid-beta-induced toxicity","volume":"134","author":"de Jager","year":"2015","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/nan.12244","article-title":"The blood clotting Factor XIIIa forms unique complexes with amyloid-beta (A\u03b2) and colocalizes with deposited A\u03b2 in cerebral amyloid angiopathy","volume":"42","author":"de Jager","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"2021111619125995800_B17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.neurobiolaging.2012.10.005","article-title":"Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy","volume":"34","author":"de Jager","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"2021111619125995800_B18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.chembiol.2010.06.019","article-title":"Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening","volume":"17","author":"Chabot","year":"2010","journal-title":"Chem. Biol."},{"key":"2021111619125995800_B19","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2353\/ajpath.2009.090012","article-title":"Calcification locates to transglutaminases in advanced human atherosclerotic lesions","volume":"175","author":"Matlung","year":"2009","journal-title":"Am. J. Pathol."},{"key":"2021111619125995800_B20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MCA.0b013e3283108fc3","article-title":"Increased tissue transglutaminase expression in human atherosclerotic coronary arteries","volume":"19","author":"Cho","year":"2008","journal-title":"Coron. Artery Dis."},{"key":"2021111619125995800_B21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/sj.cdd.4401093","article-title":"\u2018Tissue\u2019 transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington\u2019s disease","volume":"9","author":"Mastroberardino","year":"2002","journal-title":"Cell Death Differ."},{"key":"2021111619125995800_B22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3324\/haematol.2015.131441","article-title":"Coated platelets function in platelet-dependent fibrin formation via integrin \u03b1IIb\u03b23 and transglutaminase factor XIII","volume":"101","author":"Mattheij","year":"2016","journal-title":"Haematologica"},{"key":"2021111619125995800_B23","doi-asserted-by":"publisher","first-page":"31400","DOI":"10.1074\/jbc.M113.495556","article-title":"Two sides of MGP null arterial disease: chondrogenic lesions dependent on transglutaminase 2 and elastin fragmentation associated with induction of adipsin","volume":"288","author":"Beazley","year":"2013","journal-title":"J. Biol. Chem."},{"key":"2021111619125995800_B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.atherosclerosis.2012.07.044","article-title":"Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress","volume":"224","author":"Matlung","year":"2012","journal-title":"Atherosclerosis"},{"key":"2021111619125995800_B25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2009.11.014","article-title":"Effect of transglutaminase 2 (TG2) deficiency on atherosclerotic plaque stability in the apolipoprotein E deficient mouse","volume":"210","author":"Williams","year":"2010","journal-title":"Atherosclerosis"},{"key":"2021111619125995800_B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000109073","article-title":"Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases","volume":"45","author":"Pistea","year":"2008","journal-title":"J. Vasc. Res."},{"key":"2021111619125995800_B27","doi-asserted-by":"publisher","first-page":"9042","DOI":"10.1021\/jm501145a","article-title":"Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2","volume":"57","author":"Kl\u00f6ck","year":"2014","journal-title":"J. Med. Chem."},{"key":"2021111619125995800_B28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tips.2014.10.014","article-title":"Inhibitors of tissue transglutaminase","volume":"36","author":"Keillor","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"2021111619125995800_B29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/emmm.201000084","article-title":"Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease","volume":"2","author":"McConoughey","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"2021111619125995800_B30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00726-016-2295-z","article-title":"Role of tissue transglutaminase in age-associated ventricular stiffness","volume":"49","author":"Oh","year":"2017","journal-title":"Amino Acids"},{"key":"2021111619125995800_B31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12640-014-9506-8","article-title":"Inhibition of transglutaminase exacerbates polyglutamine-induced neurotoxicity by increasing the aggregation of mutant ataxin-3 in an SCA3 Drosophila model","volume":"27","author":"Lin","year":"2015","journal-title":"Neurotox. Res."},{"key":"2021111619125995800_B32","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jvs.2012.09.062","article-title":"Transglutaminase type 2 in human abdominal aortic aneurysm is a potential factor in the stabilization of extracellular matrix","volume":"57","author":"Shin","year":"2013","journal-title":"J. Vasc. Surg."},{"key":"2021111619125995800_B33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.lfs.2013.01.027","article-title":"Cystamine ameliorates ventricular hypertrophy associated with modulation of IL-6-mediated signaling in lupus-prone mice","volume":"92","author":"Tzang","year":"2013","journal-title":"Life Sci."},{"key":"2021111619125995800_B34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000327773","article-title":"Effect of cystamine on blood pressure and vascular characteristics in spontaneously hypertensive rats","volume":"48","author":"Engholm","year":"2011","journal-title":"J. Vasc. Res."},{"key":"2021111619125995800_B35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.brainres.2009.01.038","article-title":"Expression of tissue-type transglutaminase (tTG) and the effect of tTG inhibitor on the hippocampal CA1 region after transient ischemia in gerbils","volume":"1263","author":"Hwang","year":"2009","journal-title":"Brain Res."},{"key":"2021111619125995800_B36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1159\/000106465","article-title":"Chronic cystamine treatment inhibits small artery remodelling in rats","volume":"44","author":"Eftekhari","year":"2007","journal-title":"J. Vasc. Res."},{"key":"2021111619125995800_B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2004.12.011","article-title":"Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6\/2 mouse model of Huntington\u2019s disease","volume":"231","author":"Wang","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"2021111619125995800_B38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1471-4159.2004.02726.x","article-title":"Cystamine increases L-cysteine levels in Huntington\u2019s disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation","volume":"91","author":"Fox","year":"2004","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B39","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington\u2019s disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J. Neurosci."},{"key":"2021111619125995800_B40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat. Med."},{"key":"2021111619125995800_B41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1471-4159.2005.03357.x","article-title":"Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"95","author":"Van Raamsdonk","year":"2005","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B42","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pnpbp.2010.11.023","article-title":"Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases","volume":"35","author":"Gibrat","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"2021111619125995800_B43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainres.2010.03.079","article-title":"Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice","volume":"1335","author":"Sun","year":"2010","journal-title":"Brain Res."},{"key":"2021111619125995800_B44","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington\u2019s disease","volume":"21","author":"Dubinsky","year":"2006","journal-title":"Mov. Disord."},{"key":"2021111619125995800_B45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/mds.26101","article-title":"A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington\u2019s disease","volume":"30","author":"Prundean","year":"2015","journal-title":"Mov. Disord."},{"key":"2021111619125995800_B46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00240602","article-title":"Transglutaminases","volume":"58","author":"Lorand","year":"1984","journal-title":"Mol. Cell. Biochem."},{"key":"2021111619125995800_B47","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/emm.2004.74","article-title":"Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine","volume":"36","author":"Jeon","year":"2004","journal-title":"Exp. Mol. Med."},{"key":"2021111619125995800_B48","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.8b00204","article-title":"Cystamine and disulfiram inhibit human transglutaminase 2 via an oxidative mechanism","author":"Palanski","year":"2018","journal-title":"Biochemistry"},{"key":"2021111619125995800_B49","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03255.x","article-title":"Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease","volume":"94","author":"Pinto","year":"2005","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B50","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1016\/j.jchromb.2009.05.041","article-title":"Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism","volume":"877","author":"Pinto","year":"2009","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"2021111619125995800_B51","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1111\/j.1471-4159.2010.06874.x","article-title":"Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases","volume":"114","author":"Bousquet","year":"2010","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/fcp.12009","article-title":"Pharmacokinetics of cysteamine bitartrate following intraduodenal delivery","volume":"28","author":"Dohil","year":"2014","journal-title":"Fundam. Clin. Pharmacol."},{"key":"2021111619125995800_B53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1750-1172-6-86","article-title":"Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients","volume":"6","author":"Bouazza","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"2021111619125995800_B54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/toxsci\/63.1.57","article-title":"Mechanisms for the cytotoxicity of cysteamine","volume":"63","author":"Jeitner","year":"2001","journal-title":"Toxicol. Sci."},{"key":"2021111619125995800_B55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0076-6879(95)52013-9","article-title":"Promotion of cyst(e)ine uptake","volume":"252","author":"Meier","year":"1995","journal-title":"Methods Enzymol."},{"key":"2021111619125995800_B56","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.bcp.2004.12.011","article-title":"Mechanism for the inhibition of transglutaminase 2 by cystamine","volume":"69","author":"Jeitner","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"2021111619125995800_B57","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1152\/physrev.1968.48.2.424","article-title":"Biochemistry and physiology of taurine and taurine derivatives","volume":"48","author":"Jacobsen","year":"1968","journal-title":"Physiol. Rev."},{"key":"2021111619125995800_B58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09553007214551031","article-title":"Release of thiols from cellular mixed disulphides and its possible role in radiation protection","volume":"22","author":"Modig","year":"1972","journal-title":"Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med."},{"key":"2021111619125995800_B59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/09553007414551011","article-title":"Letter: a test of the \u2018mixed-disulphide\u2019 hypothesis of cysteamine radioprotection","volume":"26","author":"Power","year":"1974","journal-title":"Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med."},{"key":"2021111619125995800_B60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0891-5849(99)00051-9","article-title":"Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide","volume":"27","author":"Winterbourn","year":"1999","journal-title":"Free Radic. Biol. Med."},{"key":"2021111619125995800_B61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0925-4439(01)00091-6","article-title":"Oxidative stress increases internal calcium stores and reduces a key mitochondrial enzyme","volume":"1586","author":"Gibson","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111619125995800_B62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/107424849900400107","article-title":"Mechanisms of hydrogen peroxide-induced increase in intracellular calcium in cardiomyocytes","volume":"4","author":"Wang","year":"1999","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"2021111619125995800_B63","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0006-291X(03)00835-0","article-title":"Activation of in situ tissue transglutaminase by intracellular reactive oxygen species","volume":"305","author":"Lee","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111619125995800_B64","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.bbrc.2004.10.122","article-title":"Arachidonic acid activates tissue transglutaminase and stress fiber formation via intracellular reactive oxygen species","volume":"325","author":"Yi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021111619125995800_B65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00726-011-1209-3","article-title":"\u03b3-Glutamylamines and neurodegenerative diseases","volume":"44","author":"Jeitner","year":"2013","journal-title":"Amino Acids"},{"key":"2021111619125995800_B66","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1046\/j.1471-4159.2001.00673.x","article-title":"N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington\u2019s disease","volume":"79","author":"Jeitner","year":"2001","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1471-4159.2008.05350.x","article-title":"Increased levels of gamma-glutamylamines in Huntington disease CSF","volume":"106","author":"Jeitner","year":"2008","journal-title":"J. Neurochem."},{"key":"2021111619125995800_B68","doi-asserted-by":"publisher","first-page":"25402","DOI":"10.1074\/jbc.M109.097162","article-title":"Redox regulation of transglutaminase 2 activity","volume":"285","author":"Stamnaes","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2021111619125995800_B69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-chembioeng-080615-033553","article-title":"Thiol-disulfide exchange reactions in the mammalian extracellular environment","volume":"7","author":"Yi","year":"2016","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"2021111619125995800_B70","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1074\/jbc.RA117.001382","article-title":"Endoplasmic reticulum-resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2","volume":"293","author":"Yi","year":"2018","journal-title":"J. Biol. Chem."},{"key":"2021111619125995800_B71","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1074\/jbc.M116.767988","article-title":"Thioredoxin-1 selectively activates transglutaminase 2 in the extracellular matrix of the small intestine: implications for celiac disease","volume":"292","author":"Plugis","year":"2017","journal-title":"J. Biol. Chem."},{"key":"2021111619125995800_B72","doi-asserted-by":"publisher","first-page":"37866","DOI":"10.1074\/jbc.M111.287490","article-title":"Activation of extracellular transglutaminase 2 by thioredoxin","volume":"286","author":"Jin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2021111619125995800_B73","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1474-4422(09)70290-X","article-title":"Gluten sensitivity: from gut to brain","volume":"9","author":"Hadjivassiliou","year":"2010","journal-title":"Lancet Neurol."},{"key":"2021111619125995800_B74","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/1521-4141(200105)31:5%3c1317::AID-IMMU1317%3e3.0.CO;2-I","article-title":"T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase","volume":"31","author":"Molberg","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"2021111619125995800_B75","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2215\/CJN.12321211","article-title":"A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety","volume":"7","author":"Langman","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2021111619125995800_B76","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00467-012-2315-5","article-title":"Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up","volume":"28","author":"Dohil","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"2021111619125995800_B77","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1080\/03007995.2017.1354288","article-title":"A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis","volume":"33","author":"Medic","year":"2017","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20180691\/809717\/bsr-2018-0691c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20180691\/809717\/bsr-2018-0691c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:44:02Z","timestamp":1720449842000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/38\/5\/BSR20180691\/88222\/Cystamine-and-cysteamine-as-inhibitors-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20180691","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1186\/s40478-025-02135-4","asserted-by":"object"}]},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"article-number":"BSR20180691"}}